Accès ouvert déclaré
2022
article
Integrase inhibitors in children and adolescents: clinical use and resistance
David Torres-Fernández, Santiago Jiménez de Ory, Clàudia Fortuny, Talía Sainz, Dolores Falcón, Enrique Bernal, Miguel Cervero, Marta Navarro Vilasaró, Cristina Epalza, Marisa Navarro, José Tomás Ramos, África Holguín, Luis Prieto, María José Mellado, Luis Escosa, Milagros García López Hortelano, Carlos Grasa, Paula Rodr, Paula Rodríguez, Pablo Rojo, Alfredo Tagarro, Sara Domínguez‐Rodríguez, Álvaro Ballesteros, Marta Illán Ramos, Sara Guillén, Beatriz Soto, María Luisa Navarro, Jesús Saavedra, Arantxa Berzosa, David Aguilera, Begoña Santiago, MaAngeles Muñoz-Fernández, Amanda Bermejo, María Penín, Jorge Martínez, Katie Badillo, Ana Belén Jiménez, Adriana Navas, Eider Oñate, Itziar Pocheville, Elisa Garrote, Elena Colino, Olga Afonso, Jorge Gómez Sirvent, M. González-Ripoll Garzón, Vicente Román, Raquel Angulo, Olaf Neth, Lola Falcón-Neyra, Pedro Terol, Juan Luís, Álvaro Vázquez, Begoña Carazo, A. N. Medina, Francisco Lendínez, Mercedes Ibáñez, Estrella Peromingo, María Isabel Sánchez, Beatriz Ruiz, Ana Grande, Francisco José Romero, Carlos Pérez, Marta Pareja, Begoña Losada, Mercedes Herranz, Javier Nogueira, Matilde Bustillo Alonso, Sheila Miralbés, Pilar Collado, José Antonio Couceiro, Leticia Vila, Consuelo Calviño, Ana Isabel Piqueras, Manuel Oltra, César Gavilán, Elena Montesinos, Marta Dapena, Cristina Álvarez, Beatriz Jiménez, Ana Gloria Andrés, Víctor Marugán, Carlos Ochoa, Ana Isabel Menasalvas, Eloísa Cervantes, Beatriz Álvarez, Pere Soler‐Palacín, Maria Antoinette Frick, Clara Carreras, Lluís Mayol, Teresa Vallmanya, Olga Calavia, Lourdes García, Valentí Pineda, Neus Rius, Joaquín Dueñas, Antoni Noguera‐Julián, Marisa Montes, Eulalia Valencia, Ana Sofia Delgado, Rafael Rubio, Federico Pulido, Otilia Bisbal, Alfonso Monereo Alonso, Juan Berenguer, Cristina Díez, Teresa Aldámiz, Pedro Montilla, Elena Bermúdez, Maricela Valerio, José Sanz, Alejandra Gimeno, Rafael Torres, Santiago Moreno, María Jesús Pérez-Granda, Pablo Ryan, Jesús Troya, Jesús Sanz, Juan Emilio Losa, Rafael Hervás Gómez, Miguel Górgolas, José Antonio Iribarren, María José Aramburu, Lourdes Martínez, Ane Josune Goikoetxea, Sofía Ibarra, Mireia de la Peña, Michele Hernández, Juan Luis Gómez Sirvent, Ricardo Pelazas, María del Mar Alonso, María Remedios Alemán Valls, Ana M. López, Dácil García, Jehovana Rodríguez, Miguel Ángel Cárdenes, Luís F. López‐Cortés, Silvia Llaves, María Rios, Jesús Rodríguez, Virginia Palomo, Juan Pasquau, Coral García, José Hernández, Clara Martínez, Antonio Rivero, Ángela Camacho, Dolores Merino, Miguel Raffo, Laura Corpa, Elisa Martínez, Fernando Mateos, José Javier Blanch, Miguel Torralba, Piedad Arazo, Gloria Sampériz, Celia Miralles, Antonio Ocampo, Guille Pousada, Álvaro Mena, Marta Montero, Miguel Salavert, Inma Segarra, Marı́a José Galindo, Natalia Pretel, Joaquín Portilla, Irene Portilla, Félix Gutiérrez, Mar Masiá, Cati Robledano, Araceli Adsuar, Carmen Hinojosa, Begoña Monteagudo, Jésica Abadía, Carlos Galera, Helena Albendín, Marian Fernández, José Ramón Blanco, Joaquín Burgos, Berta Torres, Elisa de Lazzari
10Citations signalées — pas une note de qualité
17Institutions déclarées
1Pays d’affiliation déclarés
Résumé fourni par la source
BACKGROUND: Although integrase inhibitor (INI)-based regimens are now the first-line choice for all people living with HIV, experience among children and adolescents is still scarce. We describe the characteristics and outcomes of a paediatric/adolescent cohort on INI-based ART. METHODS: Retrospective analysis of HIV-infected patients below 18 years of age who started an INI-based regimen from 2007 to 2019, enrolled in the Spanish National Adult (CoRIS) and Paediatric (CoRISpe) cohorts. Resistance mutations were identified by the Stanford HIV Drug Resistance Database. RESULTS: Overall, 318 INI-based regimens were implemented in 288 patients [53.8% female; median age at start of 14.3 years (IQR 12.0-16.3)]. Most were born in Spain (69.1%), vertically infected (87.7%) and treatment-experienced (92.7%). The most frequently prescribed INI was dolutegravir (134; 42.1%), followed by raltegravir (110; 34.6%) and elvitegravir (73; 23.0%). The median exposure was 2.0 years (IQR 1.1-3.0). The main reasons to start an INI-based therapy were treatment simplification (54.4%) and virological failure (34.3%). In total, 103 (32.4%) patients interrupted their regimen: 14.5% for simplification and 8.5% due to virological failure. Most subjects who received dolutegravir (85.8%) and elvitegravir (83.6%) did not interrupt their regimen and maintained undetectable viral load. There were only five virological failures with dolutegravir and three with elvitegravir. There were no interruptions related to adverse events. Seven patients with virological failure presented major resistance mutations to INIs; none of them were on dolutegravir. CONCLUSIONS: INI-based regimens were effective and safe for HIV treatment in children and adolescents. Dolutegravir and elvitegravir presented an excellent profile, and most patients achieved and maintained viral suppression.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Integrase inhibitors in children and adolescents: clinical use and resistance
- Date Crossref
- 16/08/2022
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.
Institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Sujets associés
HIV/AIDS drug development and treatmentHIV Research and TreatmentBiochemical and Molecular Research